The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea in adults with ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Kisqali (ribociclib) combined with endocrine therapy demonstrates a sustained 28.5% reduction in distant recurrence for ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant ...

We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

The U.S. Food and Drug Administration (FDA) has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor (TKI) for treating leukemia and a range of cancers, including CML, GIST, ...

Artificial intelligence (AI) may help identify patients at risk of developing severe side effects from immune checkpoint inhibitors (ICIs) in lung cancer treatment, according to new research. The ...